Cerus Corporation (NASDAQ:CERS) shares traded -17.98% lower at $2.44 on Wall Street last session.
In accordance with the data, 5 analysts cover Cerus Corporation (NASDAQ:CERS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $11.50 and a low of $3.00, we find $7.50. Given the previous closing price of $2.97, this indicates a potential upside of 152.53 percent. CERS stock price is now -1.59% away from the 50-day moving average and -18.26% away from the 200-day moving average. The market capitalization of the company currently stands at $419.68M.
It has been rated a hold by 2 analysts and a buy by 3. Brokers who have rated the stock have averaged $7.38 as their price target over the next twelve months.
In other news, Swisher Daniel N JR, Director bought 5,000 shares of the company’s stock on May 26. The stock was bought for $9,535 at an average price of $1.91. Upon completion of the transaction, the Director now directly owns 118,808 shares in the company, valued at $0.29 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 24, Director SCHULZE GAIL bought 9,850 shares of the business’s stock. A total of $19,981 was incurred on buying the stock at an average price of $2.03. This leaves the insider owning 83,420 shares of the company worth $0.2 million. Insiders disposed of 204,740 shares of company stock worth roughly $0.5 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CERS stock. A new stake in Cerus Corporation shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $2,587,000. PORTSIDE WEALTH GROUP, LLC invested $1,379,000 in shares of CERS during the first quarter. In the first quarter, PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO acquired a new stake in Cerus Corporation valued at approximately $288,000. WOLVERINE TRADING, LLC acquired a new stake in CERS for approximately $174,000. RUSSELL INVESTMENTS GROUP, LTD. purchased a new stake in CERS valued at around $164,000 in the second quarter.
Cerus Corporation (NASDAQ: CERS) opened at $2.7300 on Thursday. During the past 12 months, Cerus Corporation has had a low of $1.76 and a high of $5.93. As of last week, the company has a debt-to-equity ratio of 1.24, a current ratio of 2.10, and a quick ratio of 1.60. The fifty day moving average price for CERS is $2.4886 and a two-hundred day moving average price translates $2.9802 for the stock.
The latest earnings results from Cerus Corporation (NASDAQ: CERS) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at -$0.06, inline with analysts’ expectations of -$0.06. This compares to -$0.07 EPS in the same period last year. The net profit margin was -25.10% and return on equity was -67.00% for CERS. The company reported revenue of $38.48 million for the quarter, compared to $43.02 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.56 percent. For the current quarter, analysts expect CERS to generate $46.73M in revenue.
Cerus Corporation(CERS) Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
